⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8770450 | 0.82 | — | — | |
| SCHEMBL15240198 | 0.72 | — | — | |
| SCHEMBL18616970 | 0.70 | — | — | |
| SCHEMBL8770491 | 0.70 | — | — | |
| SCHEMBL744617 | 0.65 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL31227464 | 0.64 | ALDH1A1 (0.47) | — | |
| SCHEMBL3796364 | 0.61 | TERT (0.40) | — | |
| SCHEMBL6365255 | 0.55 | — | — | |
| SCHEMBL31227322 | 0.50 | — | — | |
| SCHEMBL17791788 | 0.50 | NOTUM (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4271674-B9 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4271674-B3 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250340546-A1 | HSD17B13 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-11-06 | — | — | US | disclosed |
| US-20250312352-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-09 | — | — | US | disclosed |
| WO-2025104699-A1 | URACIL COMPOUNDS | ASTRAZENECA AB (SE) | 2025-05-22 | — | — | WO | disclosed |
| EP-4520393-A2 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4271674-B1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20250026745-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | MIRUM PHARMACEUTICALS, INC. | 2025-01-23 | — | — | US | disclosed |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2025-01-02 | — | — | US | disclosed |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | EPICS THERAPEUTICS (BE) | 2024-09-17 | — | — | US | disclosed |
| WO-2013049559-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20130085164-A1 | Imidazole Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2013049565-A1 | IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20130085148-A1 | Pyridine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085148-A1 | Pyridine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085148-A1 | Pyridine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085164-A1 | Imidazole Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| EP-2571882-A1 | HETEROCYCLIC FLAVIVIRIDAE VIRUS INHIBITORS | Gilead Sciences, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011146817-A1 | HETEROCYCLIC FLAVIVIRIDAE VIRUS INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011146817-A1 | HETEROCYCLIC FLAVIVIRIDAE VIRUS INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-11-24 | — | — | WO | disclosed |